1
|
Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b. Blood 2015; 125:949-58. [DOI: 10.1182/blood-2014-07-587840] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Key Points
B-cell malignancies were efficiently recognized by T cells expressing high-affinity alloHLA-restricted TCRs specific for CD79b. Aberrant expression of CD79b in non–B cells caused unwanted reactivity, rendering CD79b unsuitable for TCR-based immunotherapies.
Collapse
|
2
|
Cajiao I, Sargent R, Elstrom R, Cooke NE, Bagg A, Liebhaber SA. Igbeta(CD79b) mRNA expression in chronic lymphocytic leukaemia cells correlates with immunoglobulin heavy chain gene mutational status but does not serve as an independent predictor of clinical severity. Am J Hematol 2007; 82:712-20. [PMID: 17315213 DOI: 10.1002/ajh.20885] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The etiology of chronic lymphocytic leukemia (CLL) is poorly understood and its course is highly variable. Somatic hypermutation (SHM) of the immunoglobulin heavy chain (IgV(H)) gene and ZAP70 protein expression have been reported as prognostic indicators. However, these assays are not widely available and their concordance is imperfect. Thus a need exists to identify additional molecular determinants of CLL. The Igbeta (CD79b) subunit of the B cell antigen receptor is essential for B lymphocyte function. Defects in Igbeta expression are implicated in CLL pathogenesis. We have analyzed Igbeta mRNA expression in CLL cells in 40 consecutive patient samples. About 75% of the samples showed the expected decrease of Igbeta surface staining. Igbeta mRNA levels covered a wider range, did not correlate with Igbeta surface staining, but clearly distinguished the normal and CLL lymphocyte populations. Remarkably, Igbeta mRNA levels correlated strongly with SHM; Igbeta mRNA levels in CLL cells were significantly higher in patients with an unmutated IgV(H) gene when compared with those in whom IgV(H) was hypermutated (P = 0.008). In contrast, no correlation was observed between Igbeta mRNA levels and ZAP70 expression. Multiple parameters abstracted from chart reviews were used to estimate severity of CLL in each case. While severity correlated strongly with ZAP70 staining, and to a lesser extent with SHM status, there was no correlation with Igbeta mRNA levels. These data establish a strong linkage between Igbeta mRNA expression and SHM in CLL and highlight the complex relationships between biochemical parameters and clinical status in this disease.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Alternative Splicing/genetics
- CD79 Antigens/genetics
- CD79 Antigens/metabolism
- Cell Line
- Cell Membrane/metabolism
- Exons/genetics
- Female
- Gene Expression Regulation, Neoplastic/genetics
- Humans
- Immunoglobulin Heavy Chains/genetics
- Immunoglobulin Heavy Chains/immunology
- Immunohistochemistry
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/immunology
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Lymphocytes/metabolism
- Male
- Middle Aged
- Mutation/genetics
- RNA, Messenger/genetics
- ZAP-70 Protein-Tyrosine Kinase/metabolism
Collapse
Affiliation(s)
- Isabela Cajiao
- Department of Genetics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
| | | | | | | | | | | |
Collapse
|
3
|
Loraine AE, Helt GA, Cline MS, Siani-Rose MA. Exploring alternative transcript structure in the human genome using blocks and InterPro. J Bioinform Comput Biol 2005; 1:289-306. [PMID: 15290774 DOI: 10.1142/s0219720003000113] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2002] [Revised: 12/07/2002] [Accepted: 01/15/2003] [Indexed: 11/18/2022]
Abstract
Understanding how alternative splicing affects gene function is an important challenge facing modern-day molecular biology. Using homology-based, protein sequence analysis methods, it should be possible to investigate how transcript diversity impacts protein function. To test this, high-quality exon-intron structures were deduced for over 8000 human genes, including over 1300 (17 percent) that produce multiple transcript variants. A data mining technique (DiffMotif) was developed to identify genes in which transcript variation coincides with changes in conserved motifs between variants. Applying this method, we found that 30 percent of the multi-variant genes in our test set exhibited a differential profile of conserved InterPro and/or BLOCKS motifs across different mRNA variants. To investigate these, a visualization tool (ProtAnnot) that displays amino acid motifs in the context of genomic sequence was developed. Using this tool, genes revealed by the DiffMotif method were analyzed, and when possible, hypotheses regarding the potential role of alternative transcript structure in modulating gene function were developed. Examples of these, including: MEOX1, a homeobox-containing protein; AIRE, involved in auto-immune disease; PLAT, tissue type plasminogen activator; and CD79b, a component of the B-cell receptor complex, are presented. These results demonstrate that amino acid motif databases like BLOCKS and InterPro are useful tools for investigating how alternative transcript structure affects gene function.
Collapse
Affiliation(s)
- Ann E Loraine
- Bioinformatics Department, Affymetrix, 6550 Vallejo St, Emeryville, CA 94530 USA.
| | | | | | | |
Collapse
|
4
|
Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004; 103:4389-95. [PMID: 14962897 DOI: 10.1182/blood-2003-12-4312] [Citation(s) in RCA: 305] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Abstract
The finding that chronic lymphocytic leukemia (CLL) consists of 2 clinical subsets, distinguished by the incidence of somatic mutations in the immunoglobulin (Ig) variable region (V) genes, has clearly linked prognosis to biology. Antigen encounter by the cell of origin is indicated in both subsets by selective but distinct expression of V genes, with evidence for continuing stimulation after transformation. The key to distinctive tumor behavior likely relates to the differential ability of the B-cell receptor (BCR) to respond. Both subsets may be undergoing low-level signaling in vivo, although analysis of blood cells limits knowledge of critical events in the tissue microenvironment. Analysis of signal competence in vitro reveals that unmutated CLL generally continues to respond, whereas mutated CLL is anergized. Differential responsiveness may reflect the increased ability of post-germinal center B cells to be triggered by antigen, leading to long-term anergy. This could minimize cell division in mutated CLL and account for prognostic differences. Unifying features of CLL include low responsiveness, expression of CD25, and production of immunosuppressive cytokines. These properties are reminiscent of regulatory T cells and suggest that the cell of origin of CLL might be a regulatory B cell. Continuing regulatory activity, mediated via autoantigen, could suppress Ig production and lead to disease-associated hypogammaglobulinemia. (Blood. 2004;103:4389-4395)
Collapse
Affiliation(s)
- Freda K Stevenson
- Molecular Immunology Group, Tenovus Laboratory, Cancer Sciences Division, Southampton University Hospitals Trust, Southampton SO16 6YD, United Kingdom.
| | | |
Collapse
|
5
|
MESH Headings
- B-Lymphocytes/immunology
- B-Lymphocytes/pathology
- CD4-Positive T-Lymphocytes/immunology
- CD40 Ligand/immunology
- Cell Division
- Disease Progression
- Humans
- Immunotherapy, Adoptive
- Leukemia, Lymphocytic, Chronic, B-Cell/immunology
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Leukemia, Lymphocytic, Chronic, B-Cell/therapy
- Lymphocyte Activation
- Models, Immunological
- Stromal Cells/pathology
Collapse
|
6
|
Herren B, Burrows PD. B cell-restricted human mb-1 gene: expression, function, and lineage infidelity. Immunol Res 2003; 26:35-43. [PMID: 12403343 DOI: 10.1385/ir:26:1-3:035] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
The antigen receptor on B cells (B cell receptor [BCR]) consists of two noncovalently associated modules. Immunoglobulin genes created somatically during B cell development encode the antigen-specific component of the receptor. The Igalpha/beta heterodimer, encoded by the mb-1 and B29 genes, is necessary to escort the receptor complex to the plasma membrane. Following antigen engagement of the BCR, Igalpha/beta nucleates signal transduction and promotes endocytosis of bound antigen for intracellular degradation and presentation to helper T-cells. In this review, we outline the discovery of the mb-1 gene; summarize results from other laboratories on the function of Igalpha/beta in B cells; and conclude with our recent studies, which indicate that mb-1 is not a B-lineage-restricted gene as originally proposed.
Collapse
Affiliation(s)
- Bettie Herren
- Department of Microbiology, University of Alabama at Birmingham, 35294, USA
| | | |
Collapse
|
7
|
Cragg MS, Chan HTC, Fox MD, Tutt A, Smith A, Oscier DG, Hamblin TJ, Glennie MJ. The alternative transcript of CD79b is overexpressed in B-CLL and inhibits signaling for apoptosis. Blood 2002; 100:3068-76. [PMID: 12384401 DOI: 10.1182/blood.v100.9.3068] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The B-cell receptor (BCR) for antigen is composed of surface immunoglobulin (sIg), which provides antigen specificity, and a noncovalently associated signaling unit, the CD79a/b heterodimer. Defects in CD79 can influence both BCR expression and signaling and may explain why cells from certain malignancies, such as B-chronic lymphocytic leukemia (B-CLL), often express diminished and inactive BCR. Recently, an alternative transcript of CD79b (DeltaCD79b) has been reported that is up-regulated in B-CLL and may explain this diminished BCR expression. Here we assess the expression of DeltaCD79b in B-CLL and other lymphoid malignancies and investigate its function. High relative expression of DeltaCD79b was confirmed in most cases of B-CLL and found in 6 of 6 cases of splenic lymphomas with villous lymphocytes (SLVLs) and hairy cell leukemia. In a range of Burkitt lymphoma cell lines, expression of DeltaCD79b was relatively low but correlated inversely with the ability of the BCR to signal apoptosis when cross-linked by antibody (Ab). Interestingly, when Ramos-EHRB cells, which express low DeltaCD79b, were transfected with this transcript, they were transformed from being sensitive to anti-Fcmu-induced apoptosis to being highly resistant. Although DeltaCD79b was expressed as protein, its overexpression did not reduce the level of cell surface BCR. Finally, we showed that the inhibitory activity of DeltaCD79b depended on an intact leader sequence to ensure endoplasmic reticulum (ER) trafficking and a functional signaling immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic tail. These results point to DeltaCD79b being a powerful modulator of BCR signaling that may play an important role in normal and malignant B cells.
Collapse
MESH Headings
- Alternative Splicing
- Amino Acid Motifs
- Antigens, CD/biosynthesis
- Antigens, CD/chemistry
- Antigens, CD/genetics
- Antigens, CD/physiology
- Apoptosis/genetics
- Burkitt Lymphoma/genetics
- Burkitt Lymphoma/metabolism
- Burkitt Lymphoma/pathology
- CD79 Antigens
- Dimerization
- Endoplasmic Reticulum/metabolism
- Gene Expression Regulation, Leukemic
- Humans
- K562 Cells/metabolism
- K562 Cells/pathology
- Leukemia, Hairy Cell/genetics
- Leukemia, Hairy Cell/metabolism
- Leukemia, Hairy Cell/pathology
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/metabolism
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Lymphoma, B-Cell/genetics
- Lymphoma, B-Cell/metabolism
- Lymphoma, B-Cell/pathology
- Neoplasm Proteins/biosynthesis
- Neoplasm Proteins/chemistry
- Neoplasm Proteins/genetics
- Neoplasm Proteins/physiology
- Protein Transport
- RNA, Messenger/metabolism
- RNA, Neoplasm/metabolism
- Receptors, Antigen, B-Cell/metabolism
- Recombinant Fusion Proteins/physiology
- Splenic Neoplasms/genetics
- Splenic Neoplasms/metabolism
- Splenic Neoplasms/pathology
- Transfection
- Tumor Cells, Cultured/metabolism
- Tumor Cells, Cultured/pathology
Collapse
Affiliation(s)
- Mark S Cragg
- Tenovus Research Laboratory, Cancer Sciences Division, University of Southampton School of Medicine, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK.
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Caligaris-Cappio F, Cignetti A, Granziero L, Ghia P. Chronic lymphocytic leukaemia: a model for investigating potential new targets for the therapy of indolent lymphomas. Best Pract Res Clin Haematol 2002; 15:563-75. [PMID: 12468406 DOI: 10.1053/beha.2002.0212] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
We address two key issues whose investigation may help to define new prognostic parameters and new potential targets for therapeutic intervention. First, which are the conceptual implications of the cellular origin of indolent lymphomas? Second, how may deciphering the biology of chronic lymphocytic leukaemia (CLL) lead to the development of new modalities of treatment? The latter issue is articulated in the following three key questions. (1) Which are the molecular pathways through which the microenvironment exerts its influence on the malignant clone? (2) What are the relationships between proliferation and defective apoptosis? (3)Is there any evidence of a role for antigenic stimulation?
Collapse
MESH Headings
- Apoptosis
- Cell Transformation, Neoplastic/pathology
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell/etiology
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Lymphoma, Non-Hodgkin/etiology
- Lymphoma, Non-Hodgkin/pathology
- Models, Biological
Collapse
Affiliation(s)
- Federico Caligaris-Cappio
- Department of Oncological Sciences, University of Torino, Division of Clinical Immunology and Haematology, Ospedale Mauriziano Umberto I, Torino, Italy
| | | | | | | |
Collapse
|
9
|
Payelle-Brogard B, Magnac C, Alcover A, Roux P, Dighiero G. Defective assembly of the B-cell receptor chains accounts for its low expression in B-chronic lymphocytic leukaemia. Br J Haematol 2002; 118:976-85. [PMID: 12199775 DOI: 10.1046/j.1365-2141.2002.03759.x] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
B-cell chronic lymphocytic leukaemia (B-CLL) characteristically displays low amounts of B-cell receptor (BCR), which mainly consists of the heterodimer CD79a/CD79b bound non-covalently with the surface immunoglobulin (SIg). This heterodimer is required for SIg expression and BCR signalling. To better define the mechanisms related to low BCR expression, we have investigated transcription, protein synthesis, assembly and transport of the BCR in B-CLL cells. Our results demonstrated that: (1) there was no major defect in transcriptional expression of the B29 (CD79b) gene; (2) the BCR components were intracellularly detected, thus adequately synthesized, in almost all patients; (3) neither a genetic defect in the transmembrane region of SIg, which associated with CD79a/CD79b, nor a genetic abnormality in the chaperone protein calnexin that is involved in folding and assembly of the BCR were found; (4) a constant defect in the assembly of IgM and CD79b chains occurred leading to abnormal accumulation of both chains in different intracellular compartments; (5) in a majority of CLL patients all of the nascent IgM failed to be processed into mature chains and remained unsuitable for transport. These findings demonstrated that a post-transcriptional defect located at the BCR intracellular assembly and/or trafficking levels could be involved in its low surface expression in B-CLL.
Collapse
MESH Headings
- Antigens, CD/genetics
- Biological Transport
- CD79 Antigens
- Calnexin/genetics
- Cells, Cultured
- Gene Expression
- Humans
- Immunoglobulin M/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/immunology
- Leukemia, Lymphocytic, Chronic, B-Cell/metabolism
- Microscopy, Confocal
- Receptors, Antigen, B-Cell/analysis
- Receptors, Antigen, B-Cell/genetics
- Receptors, Antigen, B-Cell/metabolism
- Reverse Transcriptase Polymerase Chain Reaction
Collapse
|
10
|
Indraccolo S, Minuzzo S, Zamarchi R, Calderazzo F, Piovan E, Amadori A. Alternatively spliced forms of Igalpha and Igbeta prevent B cell receptor expression on the cell surface. Eur J Immunol 2002; 32:1530-40. [PMID: 12115635 DOI: 10.1002/1521-4141(200206)32:6<1530::aid-immu1530>3.0.co;2-#] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
The B cell antigen receptor (BCR) includes an Igalpha/Igbeta heterodimer non-covalently associated with surface immunoglobulin. Recently, variant Igalpha and Igbeta transcripts, arising from alternative mRNA splicing, have been reported. The present study examined the function of the potential products of these transcripts, by utilizing cDNA expression plasmids to reconstitute human BCR expression in transfected 293T cells. Spliced transcripts produced truncated proteins (deltaIgalpha and deltaIgbeta), that failed to form heterodimers with their full-length counterparts, and did not mediate transport of IgM to the cell surface. When overexpressed, both deltaIgalpha and deltaIgbeta acted as competitors of Igalpha and Igbeta, leading to down-modulated surface IgM expression, and retention of IgM in the endoplasmic reticulum. These findings document a possible novel mechanism for controlling BCR expression in B cells, based on up-regulated synthesis of components devoid of transport function.
Collapse
Affiliation(s)
- Stefano Indraccolo
- Department of Oncology and Surgical Sciences, Interuniversity Center for Research on Cancer, University of Padova, Padova, Italy.
| | | | | | | | | | | |
Collapse
|
11
|
Pers JO, Berthou C, Porakishvili N, Burdjanadze M, Le Calvez G, Abgrall JF, Lydyard PM, Youinou P, Jamin C. CD5-induced apoptosis of B cells in some patients with chronic lymphocytic leukemia. Leukemia 2002; 16:44-52. [PMID: 11840262 DOI: 10.1038/sj.leu.2402327] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Although B chronic lymphocytic leukemia (B-CLL) is characterized by prolonged survival of CD5(+) B cells in vivo, these cells apoptose spontaneously in vitro. The effect of CD5 ligation on apoptosis was studied in 27 newly diagnosed patients with B-CLL, in relation to the expression of surface IgM (sIgM), CD79b, CD38, CD72 and CD19. B cells from 15 patients (group I) were resistant to anti-CD5-induced apoptosis, whereas apoptosis above spontaneous levels was seen in the remaining 12 studied (group II). Group II was then subdivided on the basis of differences in the time required to reach maximum apoptosis: whilst B cells from seven patients underwent apoptosis by 18 h, those from the remaining five needed 36 h to apoptose. The expression of sIgM, CD5, CD79b and CD38 was higher in group II than group I, suggesting that signaling for apoptosis might operate via CD79, and that CD38 expression was required. As shown by flow cytometry and confirmed by Western blotting, apoptosis was associated with a decrease in the ratios of Bcl-2/Bax and Bcl(XL)/Bax, due to an increase in the level of Bax, but no change in that of Bcl-2. This heterogeneous apoptotic response to CD5 ligation offers an explanation for the incomplete success of anti-CD5 monoclonal therapy, and might help identify patients who would respond to such treatment.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal/immunology
- Antibodies, Monoclonal/pharmacology
- Antigens, Neoplasm/immunology
- Antigens, Neoplasm/physiology
- Apoptosis/physiology
- B-Lymphocytes/cytology
- Blotting, Western
- CD5 Antigens/immunology
- CD5 Antigens/physiology
- Female
- Flow Cytometry
- Humans
- Immunophenotyping
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Ligands
- Male
- Middle Aged
- Neoplasm Proteins/physiology
- Neoplastic Stem Cells/cytology
- Proto-Oncogene Proteins/biosynthesis
- Proto-Oncogene Proteins/physiology
- Proto-Oncogene Proteins c-bcl-2/physiology
- Severity of Illness Index
- Signal Transduction
- Tumor Cells, Cultured/cytology
- bcl-2-Associated X Protein
- bcl-X Protein
Collapse
Affiliation(s)
- J O Pers
- Institut de Synergie des Sciences et de la Santé, Brest University Medical School, Brest, France
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Ghia P, Caligaris-Cappio F. The indispensable role of microenvironment in the natural history of low-grade B-cell neoplasms. Adv Cancer Res 2000; 79:157-73. [PMID: 10818680 DOI: 10.1016/s0065-230x(00)79005-1] [Citation(s) in RCA: 84] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Follicular lymphoma (FL) and B-cell chronic lymphocytic leukemia (B-CLL) are paradigmatic examples of lymphoid malignancies in which the relevant biological mechanisms are alterations in the control of apoptosis rather than an exaggerated proliferation. This explains why low-grade B-cell neoplasms still fail to be cured with current approaches. It is becoming increasingly clear that the defective apoptosis of FL and B-CLL has to be ascribed not only to intrinsic defects of the neoplastic cells, but also to extrinsic factors that influence their behavior. Malignant B cells retain the capacity to respond to microenvironmental signals, but have devised a monothematic responsiveness. They have a specific sensitivity to anti-apoptotic signals that favor their survival, whereas they seem to have become insensitive to pro-apoptotic signals. Bystander, nontumoral cells play a fundamental (though not sufficient) role both in the onset and in the progression of these diseases. The survival of leukemic cells appears to be dependent on direct cell-cell contacts. The localization of malignant B cells in bone marrow or neoplastic follicles is not a passive adhesion phenomenon but a crucial step for their survival. Bidirectional malignant lymphocyte-nontumoral cell interactions may lead to the amplification of a microenvironment able to inhibit the apoptosis of neoplastic B cells. The pressure of antigenic selection and the role of the tumor necrosis factor receptor family through the functional survival signal provided by CD40 together with the crippled death signal exerted by CD95 are new prominent characters on the stage.
Collapse
MESH Headings
- Antigens, CD/physiology
- Apoptosis/physiology
- Bone Marrow/pathology
- CD40 Antigens/physiology
- CD40 Ligand
- CD79 Antigens
- Clonal Deletion
- Cytokines/physiology
- Dendritic Cells, Follicular/metabolism
- Fas Ligand Protein
- Germinal Center/physiology
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Leukemic Infiltration
- Lymphoma, B-Cell/pathology
- Lymphoma, Follicular/pathology
- Lymphoma, Non-Hodgkin/pathology
- Membrane Glycoproteins/physiology
- Neoplasm Proteins/physiology
- Receptors, Antigen, B-Cell/physiology
- Receptors, Tumor Necrosis Factor/physiology
- Stromal Cells/physiology
- Tumor Necrosis Factor-alpha/physiology
- fas Receptor/physiology
Collapse
Affiliation(s)
- P Ghia
- Department of Biomedical Sciences and Human Oncology, University of Torino, Italy
| | | |
Collapse
|
13
|
Gordon MS, Kato RM, Lansigan F, Thompson AA, Wall R, Rawlings DJ. Aberrant B cell receptor signaling from B29 (Igbeta, CD79b) gene mutations of chronic lymphocytic leukemia B cells. Proc Natl Acad Sci U S A 2000; 97:5504-9. [PMID: 10792036 PMCID: PMC25858 DOI: 10.1073/pnas.090087097] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Chronic lymphocytic leukemia (CLL) B cells characteristically exhibit low or undetectable surface B cell receptor (BCR) and diminished responses to BCR-mediated signaling. These features suggest that CLL cells may have sustained mutations affecting one or more of the BCR proteins required for receptor surface assembly and signal transduction. Loss of expression and mutations in the critical BCR protein B29 (Igbeta, CD79b), are prevalent in CLL and could produce the hallmark features of these leukemic B cells. Because patient CLL cells are intractable to manipulation, we developed a model system to analyze B29 mutations. Jurkat T cells stably expressing micro, kappa, and mb1 efficiently assembled a functional BCR when infected with recombinant vaccinia virus bearing wild-type B29. In contrast, a B29 CLL mutant protein truncated in the transmembrane domain did not associate with mu or mb1 at the cell surface. Another B29 CLL mutant lacking the C-terminal immunoreceptor tyrosine activation motif tyrosine and distal residues brought the receptor to the surface as well as wild-type B29 but showed significant impairment in anti-IgM-stimulated signaling events including mitogen-activated protein kinase activation. These findings demonstrate that B29 mutations previously identified in CLL patients can affect BCR-dependent signaling and may contribute to the unresponsive B cell phenotype in CLL. Finally, the features of the B29 mutations in CLL predict that they may be generated by somatic hypermutation.
Collapse
MESH Headings
- Antigens, CD/genetics
- Antigens, CD/immunology
- B-Lymphocytes/immunology
- CD79 Antigens
- Flow Cytometry
- Humans
- Immunoglobulin M/immunology
- Jurkat Cells
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/immunology
- Mutagenesis, Site-Directed
- Mutation
- Receptors, Antigen, T-Cell/genetics
- Receptors, Antigen, T-Cell/immunology
- Signal Transduction/immunology
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- M S Gordon
- Molecular Biology Institute, Department of Microbiology, Division of Immunology/Rheumatology, University of California School of Medicine, Los Angeles, CA 90095, USA
| | | | | | | | | | | |
Collapse
|
14
|
Expression of Ig-β (CD79b) by chronic lymphocytic leukemia B cells that lack immunoglobulin heavy-chain allelic exclusion. Blood 2000. [DOI: 10.1182/blood.v95.8.2725] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Abstract
Because immunoglobulin (Ig)-β (CD79b) is required for immunoglobulin allelic exclusion, we examined the CD79b expressed by four chronic lymphocytic leukemia (CLL) samples that expressed more than one immunoglobulin heavy-chain allele and five samples that had normal immunoglobulin heavy-chain allelic exclusion. All leukemia cell samples stained poorly with monoclonal antibodies specific for extracellular epitopes of CD79b. However, all samples expressed functional CD79b genes, regardless of whether they did or did not express more than one immunoglobulin heavy-chain allele. We identified variant CD79b genes that had conservative base substitutions restricted to regions encoding the extracellular immunoglobulin-like domain of CD79b. However, these variants were not restricted to samples lacking immunoglobulin heavy-chain allelic exclusion and most likely reflect genetic polymorphism. Collectively, these data indicate that the unusual expression of more than one immunoglobulin heavy allele by CLL B cells is not associated with structural, nonconservative mutations in the signal-transduction domains of CD79b.
Collapse
|
15
|
Expression of Ig-β (CD79b) by chronic lymphocytic leukemia B cells that lack immunoglobulin heavy-chain allelic exclusion. Blood 2000. [DOI: 10.1182/blood.v95.8.2725.008k27_2725_2727] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Because immunoglobulin (Ig)-β (CD79b) is required for immunoglobulin allelic exclusion, we examined the CD79b expressed by four chronic lymphocytic leukemia (CLL) samples that expressed more than one immunoglobulin heavy-chain allele and five samples that had normal immunoglobulin heavy-chain allelic exclusion. All leukemia cell samples stained poorly with monoclonal antibodies specific for extracellular epitopes of CD79b. However, all samples expressed functional CD79b genes, regardless of whether they did or did not express more than one immunoglobulin heavy-chain allele. We identified variant CD79b genes that had conservative base substitutions restricted to regions encoding the extracellular immunoglobulin-like domain of CD79b. However, these variants were not restricted to samples lacking immunoglobulin heavy-chain allelic exclusion and most likely reflect genetic polymorphism. Collectively, these data indicate that the unusual expression of more than one immunoglobulin heavy allele by CLL B cells is not associated with structural, nonconservative mutations in the signal-transduction domains of CD79b.
Collapse
|
16
|
Caligaris-Cappio F. Biology of chronic lymphocytic leukemia. REVIEWS IN CLINICAL AND EXPERIMENTAL HEMATOLOGY 2000; 4:5-21. [PMID: 11491097 DOI: 10.1046/j.1468-0734.2000.00001.x] [Citation(s) in RCA: 54] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
B-cell chronic lymphocytic leukemia (CLL) lies at the cross-roads of hematology, immunology and oncology for at least three major reasons: (a) it is the prototype of human malignancies that primarily involve defects in the induction of apoptosis; (b) CLL patients develop a severe immunodeficiency with progressive hypogammaglobulinemia; and (c) they have a high prevalence of autoimmune phenomena. Recent advances in the biology of the malignant cell in CLL lead to a scenario comprised of two basic elements: first, CLL cells are optimally organized to survive in their niches because their ability to undergo apoptosis is severely hampered; second, they have a microenvironment-dependence that promotes their extended survival, a situation that arises most probably through direct cell-to-cell contacts. In addition, CLL cells themselves are the major accessory cells in CLL, but are inefficient antigen-presenting cells. This latter defect may provide a clue to reinterpret the events of immunodeficiency and autoimmunity.
Collapse
MESH Headings
- Antigen-Presenting Cells/pathology
- Apoptosis/drug effects
- Apoptosis/immunology
- Cell Transformation, Neoplastic/genetics
- Cell Transformation, Neoplastic/immunology
- Cell Transformation, Neoplastic/pathology
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell/etiology
- Leukemia, Lymphocytic, Chronic, B-Cell/immunology
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
Collapse
Affiliation(s)
- F Caligaris-Cappio
- Divisione Universitaria di Immunologia Clinica, Ospedale Mauriziano Umberto I, Dipartimento di Scienze Biomediche e Oncologia Umana, Università di Torino, Torino, Italy
| |
Collapse
|
17
|
Abstract
The B-cell antigen receptor (BCR) comprises membrane Igs (mIgs) and a heterodimer of Ig (CD79a) and Igβ (CD79b) transmembrane proteins, encoded by the mb-1 and B29 genes, respectively. These accessory proteins are required for surface expression of mIg and BCR signaling. B cells from chronic lymphocytic leukemia (B-CLL) frequently express low to undetectable surface Ig, as well as CD79b protein. Recent work described genetic aberrations affecting B29 expression and/or function in B-CLL. Because the prevalence of CLL is increased among first degree relatives, we analyzed the B29 gene in 10 families including 2 affected members each. A few silent or replacement mutations were observed at the genomic level, which never lead to truncated CD79b protein. Both members of the same family did not harbor the same mutations. However, a single silent base change in the B29 extracellular domain, corresponding to a polymorphism, was detected on 1 allele of most patients. These results indicate that the few mutations observed in the B29 gene in these patients do not induce structural abnormalities of the CD79b protein and thus do not account for its low surface expression in B-CLL. Furthermore, genetic factors were not implicated, because identical mutations were not observed among 2 members of the same family.
Collapse
|
18
|
Benlagha K, Guglielmi P, Cooper MD, Lassoued K. Modifications of Igalpha and Igbeta expression as a function of B lineage differentiation. J Biol Chem 1999; 274:19389-96. [PMID: 10383452 DOI: 10.1074/jbc.274.27.19389] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Transcription of the mb1 and B29 genes is initiated when lymphoid progenitors enter the B cell differentiation pathway, and their transmembrane Igalpha and Igbeta products constitute essential signaling components of pre-B and B cell antigen receptors. We analyzed Igalpha/Igbeta biosynthesis, heterogeneity, and molecular interactions as a function of human B lineage differentiation in cell lines representative of the pro-B, pre-B, and B cell stages. All B lineage representatives produced a 36-kDa Igbeta form and three principal Igalpha forms, transient 33/40-kDa species and a mature 44-kDa glycoprotein. Deglycosylation revealed a major Igalpha core protein of 25 kDa and a minor 21-kDa Igalpha protein, apparently the product of an alternatively spliced mRNA. In pro-B cells, the Igalpha and Igbeta molecules existed primarily in separate unassembled pools, exhibited an immature glycosylation pattern, did not associate with surrogate light chain proteins, and were retained intracellularly. Their unanticipated association with the Lyn protein-tyrosine kinase nevertheless suggests functional potential for the Igalpha/Igbeta molecules in pro-B cells. Greater heterogeneity of the Igalpha and Igbeta molecules in pre-B and B cell lines was attributable to increased glycosylation complexity. Finally, the Igalpha/Igbeta heterodimers associated with fully assembled IgM molecules as a terminal event in B cell receptor assembly.
Collapse
Affiliation(s)
- K Benlagha
- Laboratoire d'Immunopathologie, Institut d'Hématologie, Hôpital Saint-Louis, 75475 Paris Cédex 10, France
| | | | | | | |
Collapse
|
19
|
An Alternatively Spliced Form of CD79b Gene May Account for Altered B-Cell Receptor Expression in B-Chronic Lymphocytic Leukemia. Blood 1999. [DOI: 10.1182/blood.v93.7.2327.407a08_2327_2335] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Several functional anomalies of B-chronic lymphocytic leukemia (B-CLL) cells may be explained by abnormalities of the B-cell receptor (BCR), a multimeric complex formed by the sIg homodimer and the noncovalently bound heterodimer Ig/Igβ (CD79a/CD79b). Because the expression of the extracellular Ig-like domain of CD79b has been reported to be absent in the cells of most CLL cases, we have investigated the molecular mechanisms that may account for this defect. Peripheral blood lymphocytes (PBL) from 50 patients and two cell lines (MEC1, MEC2) obtained from the PBL of one of them were studied. MEC1, MEC2, and 75% of CLL cases did not express detectable levels of the extracellular Ig-like domain of CD79b, which was nevertheless present in greater than 80% CD19+ cells from normal donors. In healthy subjects the expression of CD79b was equally distributed in CD5+ and CD5− B-cell subsets. Reverse transcription-polymerase chain reaction (RT-PCR) analysis of CD79b RNA from all patients and from MEC1 and MEC2 cell lines consistently yielded two fragments of different size (709 bp and 397 bp). The 709-bp band corresponds to CD79b entire transcript; the 397-bp band corresponds to an alternatively spliced form lacking exon 3 that encodes the extracellular Ig-like domain. Both fragments were also visible in normal PBL. The expression of the 397-bp fragment was increased in normal activated B cells, while no difference was seen between CD5+ and CD5− B cells. To obtain a more accurate estimate of the relative proportions of the two spliced forms, a radioactive PCR was performed in 13 normal and 22 B-CLL samples and the results analyzed using a digital imager. The mean value of the CD79b to the CD79b internally deleted ratio was 0.64 ± 0.20 SD in normal donors and 0.44 ± 0.27 SD in B-CLL (P = .01). Direct sequencing of 397-bp RT-PCR products and of genomic DNA corresponding to exon 3 from MEC1, MEC2, their parental cells, and five fresh B-CLL samples did not show any causal mutation. Single-strand conformation polymorphism analysis of exon 3 performed in 18 additional B-CLL cases showed a single abnormal shift corresponding to a TGT → TGC polymorphic change at amino acid 122. We propose a role for the alternative splicing of CD79b gene in causing the reduced expression of BCR on the surface of B-CLL cells. As normal B cells also present this variant, the mechanism of CD79b posttranscriptional regulation might reflect the activation stage of the normal B cell from which B-CLL derives.
Collapse
|
20
|
An Alternatively Spliced Form of CD79b Gene May Account for Altered B-Cell Receptor Expression in B-Chronic Lymphocytic Leukemia. Blood 1999. [DOI: 10.1182/blood.v93.7.2327] [Citation(s) in RCA: 80] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
AbstractSeveral functional anomalies of B-chronic lymphocytic leukemia (B-CLL) cells may be explained by abnormalities of the B-cell receptor (BCR), a multimeric complex formed by the sIg homodimer and the noncovalently bound heterodimer Ig/Igβ (CD79a/CD79b). Because the expression of the extracellular Ig-like domain of CD79b has been reported to be absent in the cells of most CLL cases, we have investigated the molecular mechanisms that may account for this defect. Peripheral blood lymphocytes (PBL) from 50 patients and two cell lines (MEC1, MEC2) obtained from the PBL of one of them were studied. MEC1, MEC2, and 75% of CLL cases did not express detectable levels of the extracellular Ig-like domain of CD79b, which was nevertheless present in greater than 80% CD19+ cells from normal donors. In healthy subjects the expression of CD79b was equally distributed in CD5+ and CD5− B-cell subsets. Reverse transcription-polymerase chain reaction (RT-PCR) analysis of CD79b RNA from all patients and from MEC1 and MEC2 cell lines consistently yielded two fragments of different size (709 bp and 397 bp). The 709-bp band corresponds to CD79b entire transcript; the 397-bp band corresponds to an alternatively spliced form lacking exon 3 that encodes the extracellular Ig-like domain. Both fragments were also visible in normal PBL. The expression of the 397-bp fragment was increased in normal activated B cells, while no difference was seen between CD5+ and CD5− B cells. To obtain a more accurate estimate of the relative proportions of the two spliced forms, a radioactive PCR was performed in 13 normal and 22 B-CLL samples and the results analyzed using a digital imager. The mean value of the CD79b to the CD79b internally deleted ratio was 0.64 ± 0.20 SD in normal donors and 0.44 ± 0.27 SD in B-CLL (P = .01). Direct sequencing of 397-bp RT-PCR products and of genomic DNA corresponding to exon 3 from MEC1, MEC2, their parental cells, and five fresh B-CLL samples did not show any causal mutation. Single-strand conformation polymorphism analysis of exon 3 performed in 18 additional B-CLL cases showed a single abnormal shift corresponding to a TGT → TGC polymorphic change at amino acid 122. We propose a role for the alternative splicing of CD79b gene in causing the reduced expression of BCR on the surface of B-CLL cells. As normal B cells also present this variant, the mechanism of CD79b posttranscriptional regulation might reflect the activation stage of the normal B cell from which B-CLL derives.
Collapse
|
21
|
Alfarano A, Circosta P, Vallario A, Camaschella C, Indraccolo S, Amadori A, Caligaris-Cappio F. Alternative Splicing of CD79a (Igα) and CD79b (Igß Transcripts in Human B-CLL Cells. Curr Top Microbiol Immunol 1999. [DOI: 10.1007/978-3-642-60162-0_30] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
22
|
Caligaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol 1999; 17:399-408. [PMID: 10458259 DOI: 10.1200/jco.1999.17.1.399] [Citation(s) in RCA: 308] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To review the recent major advances in the molecular and cell biology of B-cell chronic lymphocytic leukemia (B-CLL). METHODS We analyzed the nature of malignant B-CLL B cells and their interactions with the microenvironment. RESULTS B-CLL is a malignancy of a mantle zone-based subpopulation of anergic, self-reactive, activated CD5+ B cells devoted to the production of polyreactive natural autoantibodies. It is the quintessential example of a human malignancy that primarily involves defects in the induction of programmed cell death. An abnormal karyotype is observed in about 50% of patients with B-CLL. Patients with 13q14 abnormalities show heavy somatic mutation and have a benign disease. Trisomy 12 is associated with unmutated VH genes, atypical cellular morphology, and progressive disease. Extended cell survival is further shielded by a kinetic refractoriness likely promoted by abnormalities of the B-cell antigen receptor complex and favored by some cytokines that highlight a reciprocal dialog between malignant B and T cells. Because the tumor cells act as the major accessory cells, the accumulating malignant B-cell population per se is a hurdle to the production of normal antibodies and leads to a progressive and severe hypogammaglobulinemia. Conceivably, in the presence of certain immunoglobulin genes and when the T-cell control becomes deficient, activated malignant B cells may become able to present self-antigens and drive residual normal B cells to produce polyclonal autoantibodies restricted to self-antigens expressed only by blood cells and cause autoimmune cytopenias. CONCLUSION The distinctiveness of B-CLL B cells explains why B-CLL is different from other B-cell tumors and accounts for the development of immune deficiency and autoimmunity.
Collapse
Affiliation(s)
- F Caligaris-Cappio
- Dipartimento di Scienze Biomediche e Oncologia Umana, Università di Torino, Ospedale Mauriziano Umberto I, Italy.
| | | |
Collapse
|
23
|
Wang H, Diamond RA, Rothenberg EV. Cross-lineage expression of Ig-beta (B29) in thymocytes: positive and negative gene regulation to establish T cell identity. Proc Natl Acad Sci U S A 1998; 95:6831-6. [PMID: 9618498 PMCID: PMC22652 DOI: 10.1073/pnas.95.12.6831] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Developmental commitment involves activation of lineage-specific genes, stabilization of a lineage-specific gene expression program, and permanent inhibition of inappropriate characteristics. To determine how these processes are coordinated in early T cell development, the expression of T and B lineage-specific genes was assessed in staged subsets of immature thymocytes. T lineage characteristics are acquired sequentially, with germ-line T cell antigen receptor-beta transcripts detected very early, followed by CD3epsilon and terminal deoxynucleotidyl transferase, then pTalpha, and finally RAG1. Only RAG1 expression coincides with commitment. Thus, much T lineage gene expression precedes commitment and does not depend on it. Early in the course of commitment to the T lineage, thymocytes lose the ability to develop into B cells. To understand how this occurs, we also examined expression of well defined B lineage-specific genes. Although lambda5 and Ig-alpha are not expressed, the mu 0 and I mu transcripts from the unrearranged IgH locus are expressed early, in distinct patterns, then repressed just before RAG1 expression. By contrast, RNA encoding the B cell receptor component Ig-beta was found to be transcribed in all immature thymocyte subpopulations and throughout most thymocyte differentiation. Ig-beta expression is down-regulated only during positive selection of CD4(+)CD8(-) cells. Thus several key participants in the B cell developmental program are expressed in non-B lineage-committed cells, and one is maintained even through commitment to an alternative lineage, and repressed only after extensive T lineage differentiation. The results show that transcriptional activation of "lymphocyte-specific" genes can occur in uncommitted precursors, and that T lineage commitment is a composite of distinct positive and negative regulatory events.
Collapse
Affiliation(s)
- H Wang
- Stowers Institute for Medical Research, California Institute of Technology, Pasadena, CA 91125, USA
| | | | | |
Collapse
|
24
|
Ghia P, ten Boekel E, Sanz E, de la Hera A, Rolink A, Melchers F. Ordering of human bone marrow B lymphocyte precursors by single-cell polymerase chain reaction analyses of the rearrangement status of the immunoglobulin H and L chain gene loci. J Exp Med 1996; 184:2217-29. [PMID: 8976177 PMCID: PMC2196361 DOI: 10.1084/jem.184.6.2217] [Citation(s) in RCA: 151] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
CD19+CD10+ human B lineage bone marrow cells were separated into cycling or resting cells, which differ in their expression of CD34, VpreB, recombination activating gene (RAG-1), and terminal deoxynucleotidyl transferase (TdT). Polymerase chain reaction analyses developed for DHJH and VkJk, VkJkK(de) and VkK(de) rearrangements with DNA of single cells and a comparison with B lineage cell development in mouse bone marrow, allow to delineate the human B lymphocyte pathway of development as follows: CD34+VpreB+RAG-1+TdT+, DHJH-rearranged, kL germline cycling pre-B I cells-->CD34-VpreB+microH chain+ (pre-B receptor+) RAG-1-TdT-, VHDHJH-rearranged, kL germline, cycling pre-B II cells-->CD34-VpreB-, intracytoplasmic microH chain+ (pre-B receptor-) RAG-1+/-TdT-, VHDHJH-rearranged, mainly kL germline cycling pre-B II cells-->CD34-VpreB-intracytoplasmic microH chain+, RAG-1+TdT-, VHDHJH-rearranged, VkJk-rearranged, IgM-, resting pre-B II cells CD34+VpreB-, sIgM+, RAG-1+TdT-, VHDHJH- and VkJk-rearranged IgM+ immature B cells-->CD34-, CD10-, sIgM+/sIgD+ mature B cells. This order, for the first time established for human B lineage cells, shows striking similarities with that established for mouse B lineage cells in bone marrow.
Collapse
Affiliation(s)
- P Ghia
- Basel Institute for Immunology, Switzerland
| | | | | | | | | | | |
Collapse
|